Raymond James & Associates Beam Therapeutics Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$29.86 - $62.36 $124,307 - $259,604	-4,163 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$53.73 - $82.16 $67,860 - $103,768	1,263 Added 43.55%	4,163 $239,000
Q4 2021 Feb 08, 2022	BUY	$68.02 - $99.06 $197,258 - $287,274	2,900 New	2,900 $231,000
Q3 2021 Nov 02, 2021	SELL	$84.37 - $133.6 $205,525 - $325,449	-2,436 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$64.12 - $128.71 $156,196 - $313,537	2,436 New	2,436 $314,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.